Quarter Financials

Cleveland Biolabs Inc

Cleveland Biolabs Inc (CBLI)

$2.02
0.12 (+6.32%)

Income Statement

Balance Sheet Statement

Year 2020 Q2 2020 Q1 2019 Q4 2019 Q3 2019 Q2 2019 Q1 2018 Q4 2018 Q3 2018 Q2 2018 Q1 2017 Q4
Short-term debt -----------
Other Assets 0.260.280.150.140.130.150.090.090.060.100.06
Total current liabilities 2.212.161.801.590.911.010.940.571.521.090.79
Cash and cash equivalents 4.234.594.014.383.622.802.241.491.131.063.41
Long-term debt -----------
Cash and short-term investments 8.797.686.535.344.123.342.631.911.581.423.77
Total debt -----------
Inventories -----------
Deferred revenue -----------
Goodwill and Intangible Assets -----------
Total non-current liabilities 5.225.175.135.105.075.075.055.035.044.995.00
Total non-current assets 0.050.060.060.060.060.050.040.040.030.030.01
Total liabilities 7.437.336.936.705.996.085.995.596.566.085.79
Total assets 9.638.377.065.704.533.783.092.232.041.864.08
Other comprehensive income -0.52-0.51-0.57-0.59-0.61-0.58-0.57-0.58-0.57-0.64-0.61
Short-term investments 4.563.102.520.960.500.540.400.430.450.360.36
Property, Plant & Equipment Net 0.020.030.030.030.030.020.020.020.020.010.01
Net Debt -4.23-4.59-4.01-4.38-3.62-2.80-2.24-1.49-1.13-1.06-3.41
Investments 4.563.102.520.960.500.540.400.430.450.360.36
Total shareholders equity 2.201.040.13-1.00-1.45-2.30-2.91-3.36-4.52-4.21-1.71
Retained earnings (deficit) -160.45-161.67-162.52-163.63-164.06-164.93-165.55-166.00-167.17-167.29-167.66
Long-term investments -----------
Receivables -----------
Payables -----------
Total current assets 9.588.317.005.644.483.733.052.192.001.834.07

Cash Flow Statement

Year 2020 Q2 2020 Q1 2019 Q4 2019 Q3 2019 Q2 2019 Q1 2018 Q4 2018 Q3 2018 Q2 2018 Q1 2017 Q4
Operating Cash Flow -1.28-1.20-1.08-1.16-1.17-0.83-0.76-0.71-0.36-0.43-0.48
Free Cash Flow -1.28-1.22-1.08-1.16-1.18-0.83-0.76-0.71-0.37-0.43-0.48
Capital Expenditure --0.02--0.00-0.01----0.00--
Depreciation & Amortization --0.010.000.000.000.000.000.000.000.00
Acquisitions and disposals -----------
Deferred income taxes -----------
Investment purchases -2.50-1.95-2.20-2.65-0.94--0.38-0.42-0.44--
Accounts payables 0.810.44-0.18-0.07-0.52-0.000.04-0.340.970.00-0.02
Sales/Maturities of investments -----------
Change in working capital -0.080.61-0.030.09-0.56-0.030.02-0.210.830.010.11
Debt repayment -----------
Other non-cash items --0.56-0.18-0.13-0.160.10-0.15-0.04-0.020.16-0.21
Investing Cash Flow 0.921.500.511.550.41-0.19-0.03-0.00-0.04
Cash at beginning of period 4.594.234.594.014.383.622.802.241.491.131.06
Stock-based compensation -----------
Net cash flow / Change in cash -0.360.36-0.580.37-0.76-0.82-0.56-0.75-0.36-0.072.35
Effect of forex changes on cash ---0.01-0.020.000.010.01-0.010.00-0.020.00
Financing Cash Flow -0.06--0.00-----0.382.78
Dividend payments -----------
Accounts receivables -0.080.160.160.16-0.05-0.03-0.030.13-0.150.010.11
Cash at end of period 4.234.594.014.383.622.802.241.491.131.063.41
Net cash provided by operating activities -1.28-1.20-1.08-1.16-1.17-0.83-0.76-0.71-0.36-0.43-0.48
Other working capital 7.376.155.204.053.562.712.111.630.480.753.28
Inventory -----------

Retained Earning Schedule

Year 2017 Q4 2018 Q1 2018 Q2 2018 Q3 2018 Q4 2019 Q1 2019 Q2 2019 Q3 2019 Q4 2020 Q1 2020 Q2
Net Income -1-1-1-1-0-1-1-0-1-1-0
Dividend Paid -----------
Retained Earnings -160-162-163-164-164-165-166-166-167-167-168

PPE Schedule

Year 2017 Q4 2018 Q1 2018 Q2 2018 Q3 2018 Q4 2019 Q1 2019 Q2 2019 Q3 2019 Q4 2020 Q1 2020 Q2
Capital Expenditure --0--0-0----0--
Net PPE 00000000000

Intangible and Goodwill Schedule

Year 2017 Q4 2018 Q1 2018 Q2 2018 Q3 2018 Q4 2019 Q1 2019 Q2 2019 Q3 2019 Q4 2020 Q1 2020 Q2
New Purchases -2-2-2-3-1--0-0-0--
Intangible and Goodwill -----------